Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

Basit Öğe Kaydı
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorMert, Duygu
dc.contributor.authorAy, Muzeyyen
dc.contributor.authorDal, Tuba
dc.contributor.authorKaya, Safak
dc.contributor.authorYildirim, Necmettin
dc.contributor.authorGulsun, Serda
dc.date.accessioned2024-04-24T17:20:57Z
dc.date.available2024-04-24T17:20:57Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractAIM: To evaluate the effects of tenofovir disoproxil fumarate (TDF) use during late pregnancy to reduce hepatitis B virus (HBV) transmission in highly viremic mothers. METHODS: This retrospective study included 45 pregnant patients with hepatitis B e antigen (+) chronic hepatitis B and HBV DNA levels > 10(7) copies/mL who received TDF 300 mg/d from week 18 to 27 of gestation (n = 21). Untreated pregnant patients served as controls (n = 24). All infants received 200 IU of hepatitis B immune globulin (HBIG) within 24 h postpartum and 20 mu g of recombinant HBV vaccine at 4, 8, and 24 wk. Perinatal transmission rate was determined by hepatitis B surface antigen and HBV DNA results in infants at week 28. RESULTS: At week 28, none of the infants of TDF-treated mothers had immunoprophylaxis failure, whereas 2 (8.3 %) of the infants of control mothers had immunoprophylaxis failure (P = 0.022). There were no differences between the groups in terms of adverse events in mothers or congenital deformities, gestational age, height, or weight in infants. At postpartum week 28, significantly more TDF-treated mothers had levels of HBV DNA < 250 copies/mL and normalized alanine aminotransferase compared with controls (62% vs none, P < 0.001; 82% vs 61%, P = 0.012, respectively). CONCLUSION: TDF therapy during the second or third trimester reduced perinatal transmission rates of HBV and no adverse events were observed in mothers or infants. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.en_US
dc.identifier.doi10.3748/wjg.v19.i48.9377
dc.identifier.endpage9382en_US
dc.identifier.issn1007-9327
dc.identifier.issn2219-2840
dc.identifier.issue48en_US
dc.identifier.pmid24409065
dc.identifier.scopus2-s2.0-84891460915
dc.identifier.scopusqualityQ1
dc.identifier.startpage9377en_US
dc.identifier.urihttps://doi.org/10.3748/wjg.v19.i48.9377
dc.identifier.urihttps://hdl.handle.net/11468/19315
dc.identifier.volume19en_US
dc.identifier.wosWOS:000329129700024
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectTenofoviren_US
dc.subjectReverse Transcriptase Inhibitorsen_US
dc.subjectVertical Transmissionen_US
dc.subjectChronicen_US
dc.titleEfficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infectionen_US
dc.titleEfficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu